PlexusDx provides transparent, predictable monthly costs that eliminate insurance approval delays
The phase 2 diabetes trial (published in The Lancet) used the same general titration framework but with more intensive metabolic monitoring
Insulin resistance drives both type 2 diabetes and cardiovascular disease through overlapping mechanisms
It is expected to be in the market by 2026 or 2027
The random-effects model, based on the DerSimonian and Laird methods, was chosen under the assumption that the true effect size may vary across studies due to clinical and methodological differences
Retatrutide Storage, Travel & Handling: Everything You Need to Know Introduction Retatrutide stability data published by Eli Lilly in Phase 2 supports the standard GLP-1-class storage profile: refrigerated long-term, room temperature for limited periods, protected from light and freezing